Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $48,288 | 20 | 84.9% |
| Travel and Lodging | $4,774 | 20 | 8.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,913 | 7 | 3.4% |
| Food and Beverage | $1,725 | 31 | 3.0% |
| Education | $183.16 | 5 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21,779 | 27 | $0 (2024) |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $14,383 | 14 | $0 (2022) |
| Boehringer Ingelheim International GmbH | $7,671 | 9 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $5,735 | 13 | $0 (2018) |
| Genentech, Inc. | $2,750 | 5 | $0 (2024) |
| Eli Lilly and Company | $1,600 | 1 | $0 (2023) |
| Actelion Pharmaceuticals US, Inc. | $1,550 | 1 | $0 (2022) |
| Amgen Inc. | $532.17 | 10 | $0 (2020) |
| ABBVIE INC. | $483.39 | 2 | $0 (2024) |
| Incyte Corporation | $400.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,610 | 6 | Boehringer Ingelheim Pharmaceuticals, Inc. ($2,526) |
| 2023 | $1,600 | 1 | Eli Lilly and Company ($1,600) |
| 2022 | $5,438 | 6 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. ($2,400) |
| 2021 | $1,000 | 2 | Genentech, Inc. ($1,000) |
| 2020 | $8,812 | 19 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,401) |
| 2019 | $14,666 | 15 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,449) |
| 2018 | $21,588 | 31 | Mitsubishi Tanabe Pharma Development America, Inc. ($9,739) |
| 2017 | $169.00 | 3 | Mitsubishi Tanabe Pharma Development America, Inc. ($169.00) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $432.49 | General |
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,960.00 | General |
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $432.49 | General |
| 11/14/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $50.90 | General |
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $133.85 | General |
| 01/18/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 09/25/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 12/20/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $338.12 | General |
| Category: RESPIRATORY | ||||||
| 12/16/2022 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Consulting Fee | Cash or cash equivalent | $1,550.00 | General |
| Category: Cardiology | ||||||
| 10/24/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| 07/27/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 07/08/2022 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 04/28/2022 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 08/19/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 03/09/2021 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 10/25/2020 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $390.69 | General |
| Category: RESPIRATORY | ||||||
| 10/12/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Education | In-kind items and services | $7.08 | General |
| 08/27/2020 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $183.85 | General |
| Category: RESPIRATORY | ||||||
| 07/23/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Education | In-kind items and services | $7.08 | General |
| 06/04/2020 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $505.55 | General |
| Category: RESPIRATORY | ||||||
| 03/30/2020 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $217.27 | General |
| Category: RESPIRATORY | ||||||
| 02/25/2020 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $16.64 | General |
| 02/19/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $5,450.00 | General |
| Category: RESPIRATORY | ||||||
| 02/19/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
| 02/19/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 95 | 120 | $38,896 | $13,209 |
| 2022 | 3 | 72 | 98 | $32,570 | $11,149 |
| 2021 | 3 | 75 | 99 | $40,832 | $11,303 |
| 2020 | 3 | 67 | 82 | $35,595 | $6,864 |
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 45 | 61 | $19,566 | $7,728 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 34 | $9,376 | $2,754 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $3,048 | $1,643 | 53.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 13 | $6,906 | $1,084 | 15.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 55 | $16,288 | $6,562 | 40.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 30 | $12,980 | $2,446 | 18.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $3,302 | $2,141 | 64.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 45 | $18,270 | $5,283 | 28.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 37 | $16,744 | $3,194 | 19.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $5,818 | $2,826 | 48.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 33 | 45 | $15,972 | $2,814 | 17.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 25 | $11,858 | $2,205 | 18.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 12 | 12 | $7,765 | $1,845 | 23.8% |
About Dr. Lorinda Chung, MD
Dr. Lorinda Chung, MD is a Internal Medicine healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427026442.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lorinda Chung, MD has received a total of $56,883 in payments from pharmaceutical and medical device companies, with $3,610 received in 2024. These payments were reported across 83 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($48,288).
As a Medicare-enrolled provider, Chung has provided services to 309 Medicare beneficiaries, totaling 399 services with total Medicare billing of $42,525. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Palo Alto, CA
- Active Since 03/08/2006
- Last Updated 04/28/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1427026442
Products in Payments
- OFEV (Drug) $26,507
- ORENCIA (Biological) $5,735
- OPSUMIT (Drug) $1,550
- Enbrel (Biological) $370.16
- Prolia (Biological) $56.65
- EVENITY (Biological) $46.79
- NINTEDANIB (Drug) $37.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Palo Alto
Dr. Teck Ling, Md, MD
Internal Medicine — Payments: $900,598
Jennie Crews
Internal Medicine — Payments: $486,491
Byron Lee, Md, MD
Internal Medicine — Payments: $330,042
Bita Fakhri, M.d., M.p.h, M.D., M.P.H
Internal Medicine — Payments: $151,916
Curtis Chong, Md, Phd, MD, PHD
Internal Medicine — Payments: $122,210
Dr. Richard Mamelok, M.d, M.D
Internal Medicine — Payments: $120,882